{"brief_title": "Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease", "brief_summary": "OBJECTIVES: I. Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with Gaucher disease.", "detailed_description": "PROTOCOL OUTLINE: Patients are treated with intravenous glucocerebrosidase every 2 weeks. The dose is based on clinical severity of disease and response to therapy.", "condition": "Gaucher's Disease", "intervention_type": "Drug", "intervention_name": "glucocerebrosidase", "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Gaucher disease with glucocerebrosidase deficiency confirmed by enzymatic or molecular assay At least 3 organ systems affected, based on the following criteria: Anemia Thrombocytopenia Organomegaly Bone deterioration on radiograph Pulmonary compromise Symptoms compromise daily activities or risk longevity No neurologic disease", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00004293.xml"}